Stifel assumes coverage on Sage Therapeutics (NASDAQ: SAGE) with a Buy rating and a price target of $239.00.

Analyst Paul Matteis assumes coverage, maintains Buy and raises the PT to $239.00 (from $198.00)

For an analyst ratings summary and ratings history on Sage Therapeutics click here. For more ratings news on Sage Therapeutics click here.

Shares of Sage Therapeutics closed at $145.68 yesterday.